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Patients with EGFR-mutant lung adenocarcinomas
(LUADs) who initially respond to first-generation tyro-
sine kinase inhibitors (TKIs) develop resistance to
these drugs. A combination of the irreversible TKI afa-
tinib and the EGFR antibody cetuximab can be used
to overcome resistance to first-generation TKIs; how-
ever, resistance to this drug combination eventually
emerges. We identified activation of the mTORC1
signaling pathway as a mechanism of resistance to
dual inhibitionofEGFR inmousemodels. Theaddition
of rapamycin reversed resistance in vivo. Analysis of
afatinib-plus-cetuximab-resistant biopsy specimens
revealed thepresenceofgenomicalterations ingenes
that modulate mTORC1 signaling, including NF2 and
TSC1. These findings pinpoint enhanced mTORC1
activation as a mechanism of resistance to afatinib
plus cetuximab and identify genomic mechanisms
that lead to activation of this pathway, revealing a
potential therapeutic strategy for treating patients
with resistance to these drugs.
INTRODUCTION
Targeted therapies effectively treat subsets of solid cancers.
However, the inevitable development of acquired resistance
(AR) has hampered their success. A paradigm for this conceptis the case of epidermal growth factor receptor (EGFR)-mutant
lung cancer. EGFR mutations (exon 19 deletions or the L858R
point mutation) are associated with sensitivity to the first-gener-
ation tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib (Pao
and Chmielecki, 2010), but drug resistance emerges on average
1 year after TKI treatment. In 50% of resistant tumors, the
mutant EGFR allele has acquired a secondary mutation in exon
20 (T790M) (Pao and Chmielecki, 2010). Additional mechanisms
of resistance include amplification of other receptor tyrosine
kinases (RTKs) likeMET and HER2 (ERBB2), mutations in genes
encoding downstream signaling components, or phenotypic
transformations such as epithelial-to-mesenchymal transition
(EMT) and neuroendocrine differentiation (Ohashi et al., 2013).
In a previous study using transgenic mice with
EGFRL858R+T790M-induced lung adenocarcinomas (LUADs), we
showed that resistance due to EGFR T790M could be overcome
using a combination of afatinib plus cetuximab (A+C) (Regales
et al., 2009). Afatinib is a second-generation TKI that covalently
binds EGFR at cysteine 797, while cetuximab is an anti-EGFR
antibody. This preclinical study prompted a phase IB/II clinical
trial testing this drug combination in patients with progressive
disease after TKI treatment. The trial showed an overall 32%
response rate with a median duration of response of 8 months
(Janjigian et al., 2012). Unfortunately, patients responding to
the drug combination still develop progressive disease.
We used xenografts and transgenic mice to model AR to the
combination of A+C. Molecular analysis of resistant tumors re-
vealed activation of the mTOR signaling pathway. Consistent
with these findings, two separate patients with A+C-resistant tu-
mors exhibited alterations in genes (NF2 and TSC1) that whenCell Reports 7, 999–1008, May 22, 2014 ª2014 The Authors 999
(legend on next page)
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silenced in EGFR-mutant cells led to activation of the mTOR
pathway. In vitro and in vivo, A+C resistance can be overcome
by addition of an mTOR pathway inhibitor. These studies
demonstrate mechanisms of AR to dual inhibition of EGFR in
EGFR-mutant lung cancer and provide new insight into the
biology of this subset of lung cancers, with immediate therapeu-
tic implications for patients.
RESULTS
Acquired Resistance to A+C Combination Therapy in
Xenografts
We previously modeled AR to erlotinib in tetracycline-inducible
mouse models of EGFR-dependent lung cancer by intermittently
treating mice with the TKI (Politi et al., 2010). We observed clini-
cally relevantmechanisms of AR, such as the EGFRT790Mmuta-
tion andMet amplification, validating this experimental approach.
Weadopted thesamestrategy toestablishmodelsof resistance to
A+C, first in xenograft models using the PC-9/BRc1 human LUAD
cell line that harbors an EGFRDE746-A750+T790M mutation (Chmie-
lecki et al., 2011). Immunocompromised mice with PC-9/BRc1-
induced tumors were randomized to receive either vehicle (n = 5)
or A+C (n = 10). After 1 month of treatment, drug administration
was interrupted for 1 month, and this on/off drug treatment
regimenwas repeated three times (Figure1A). All tumors in control
mice grewcontinuously. In theA+C-treated cohort, tumors initially
regressed. During the third cycle of treatment, two tumors (#16
and #24) became resistant (Figure 1A). These were reimplanted
into mice and treated with A+C or vehicle alone for 4 weeks (Fig-
ure 1B). Eventually, we collected four A+C-resistant transplants
from tumor #16 (labeled 16T-7, 16T-8, 16T-9, and 16T-10) and
two from tumor #24 (24T-6 and 24T-10) (Table S1). Cell lines
were established from tumors 16T-10 and 24T-10. Resistance to
A+C in these cell lines compared to parental PC-9 and PC-9/
BRc1 cells was confirmed in a 3D colony assay (Figure S1A).
Evidence for mTOR Pathway Activation in A+C-
Resistant Xenografts
To identify mechanisms of resistance to A+C, we performedmo-
lecular analyses of the tumors collected. We first asked whether
resistance to A+C could be explained by the acquisition of new
mutations in EGFR or ERBB2, both of which are targets of
A+C. Sequencing of control and A+C-resistant tumors did notFigure 1. Activation of the mTOR Pathway in Afatinib plus Cetuximab-
(A) Representation of the intermittent dosing protocol used to generate acquired
BRc1 cells were injected subcutaneously into the flanks of immunocompromised
vehicle (n = 5, in black) or A+C (n = 10, in color). After 1month of treatment, drug ad
three times. Tumor volume measurements are shown. Tumors indicated by the a
(B) Tumor growth of the transplants derived from A+C-resistant tumors #16 (left) a
and treated continuously with vehicle (in black, n = 5) or A+C (in color, n = 5). Trans
(#16 or 24), the letter ‘‘T,’’ and a number.
(C) Immunoblotting analysis of extracts from PC-9/BRc1, 16T-10, and 24T-10 cell
Lysates were probed with the indicated antibodies; p, phospho.
(D) Immunoblotting analyses of tumor lysates from vehicle- and A+C-treated trans
the indicated antibodies; p, phospho.
(E) Hematoxylin and eosin staining (H&E) and IHC performed on paraffin sections
were stained with antibodies to EGFR exon 19 deletion mutant (EGFRDEL) and ph
20 mm.detect any mutations in EGFR and ERBB2 (data not shown).
Analysis of the tumors revealed increased EGFR copy number
in both vehicle-treated and A+C-resistant tumors compared to
the parental PC-9/BRc1 cell line with tumor #16, but not #24,
exhibiting high-level EGFR amplification (Figure S1B).Minor fluc-
tuations in ERBB2, MET, and IGF1R copy number were also
observed, the significance of which is likely limited given the
magnitude of these changes. Together, the copy number data
suggested that RTK amplification alone could not explain the
resistance phenotype observed in our samples.
These results prompted us to further investigate RTK levels
and pathway activation in A+C-resistant samples. The xeno-
graft-derived cell lines exhibited higher levels of phospho
(p)-EGFR, pERK, and pAKT compared to parental PC-9/BRc1
cells. However, the levels of activation of these proteins
decreased in the presence of A+C, suggesting that the drugs re-
tained the ability to block these pathways in A+C-resistant cells
(Figure 1C). Interestingly, drug treatment did not affect the levels
of pS6 or p4EBP1, markers of mTOR pathway activation, in the
A+C-resistant lines in contrast to parental PC-9/BRc1 cells.
This evidence suggests that pathway rewiring in resistant tumor
cells leads to sustained activation of the mTORC1 pathway.
Similarly, in vivo, the mTOR pathway was consistently engaged
in all A+C-resistant xenografts, as measured by pS6 and
p4EBP1 (Figures 1D and 1E). The levels of pAKT and pERK in
the xenografts did not reveal a consistent pattern that would
support either playing a major role in resistance to A+C in this
model (Figure 1D). Together, these results suggest that while
pAKT and pERK can be inhibited in A+C-resistant tumors, the tu-
mors retain sustained activation ofmTOR signaling thatmay play
a role in resistance to A+C combination therapy. Whole-exome
sequencing (WES) of the A+C-resistant #16 and #24 tumors
did not detect mutations in 23 mTOR-pathway related genes,
strongly suggesting that nonmutational processes account for
sustained activation of this pathway in these tumors.
Highly Penetrant Resistance to A+C in Genetically
Engineered Mouse Models of EGFR-Mutant Lung
Cancer
In parallel,wedevelopedmodelsof resistance toA+Cusing trans-
genic mice with EGFRL858R+T790M-induced LUADs. Tumors in
thesemice are resistant to erlotinib but sensitive to A+C (Regales
et al., 2009). Thirty-eight CCSP-rtTA; TetO-EGFRL858R+T790MResistant Xenografts
resistance to afatinib and cetuximab in xenografts. Approximately 106 PC-9/
mice. When tumors reached a volume of 150 mm3, mice were treated with
ministration was stopped for 1month. The intermittent drug cycle was repeated
rrows (#16 and #24) acquired resistance to A+C.
nd #24 (right). The resistant tumors were further transplanted into ten nudemice
plants are labeled with the number of the original tumor they were derived from
s treated with afatinib (100 nM), cetuximab (10 mg/ml), or the A+C combination.
plants derived from A+C-resistant tumors 16 and 24. Lysates were probed with
of tumors derived from vehicle- and A+C-treated mice as indicated. Sections
ospho-S6 (pS6) as indicated. Original magnification 340 is shown. Scale bars,
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tumor-bearing mice were cycled on and off A+C using the proto-
col used for the xenograft experiments (Figure 2A). Tumor burden
before and during treatment was tracked using magnetic reso-
nance imaging at the beginning and end of each drug cycle.
This on/off drug treatment schedule was repeated until lung tu-
mors no longer responded to treatment and increased in size on
magnetic resonance images (Figure 2A). All 38 mice that under-
went the intermittent dosing treatment protocol developed resis-
tance to the A+C combination. The majority of mice developed
resistance after three cycles of A+C (21 out of 38); 15 mice devel-
oped resistance after two cycles and twomice after four cycles of
drug treatment (Table S2A). The median tumor shrinkage during
the first cycle of A+C was 80%, but this was attenuated during
the second and third cycles of treatment (Figure 2B). Six mice
that were treated without interruption with A+C also developed
resistance to the drug combination (Figure S2A; Table S2B).
Consistent with the emergence of resistance, tumors from the
mice with AR displayed higher levels of proliferation and lower
levelsof apoptosiscompared to tumors frommice that hadunder-
gone short-term A+C treatment (Figure S2B).
We explored whether A+C-resistant tumors showed any
phenotypic differences compared to untreated tumors. CCSP-
rtTA; TetO-EGFRL858R+T790M mice developed solid and papillary
LUADs positive for the type II pneumocyte marker surfactant
protein-C (SP-C) and for thyroid transcription factor-1 (TTF1)
(Figure 2C). While most untreated adenocarcinomas were papil-
lary, A+C-treated and resistant tumors almost invariably were
solid and more poorly differentiated (Figure 2C).
Evidence for mTOR Pathway Activation in the
A+C-Resistant Mouse LUADs
To elucidate further the pathways that may account for resis-
tance to A+C, we sequenced the EGFR transgene and Erbb2
from 23 resistant tumors. Similar to our observations in xeno-
grafts, we did not find mutations in these genes or in Pik3ca,
Pik3cb, and Kras (n = 15; data not shown). A+C-resistant mouse
LUADs did not show copy number alterations in the EGFR trans-
gene or in endogenous Egfr, Erbb2,Met, and Igf1r (Figure S2C).
We then examined which signaling events might promote AR
to A+C. As expected, we found that upon short-term (5 day)
A+C treatment, phosphorylation of EGFR and Erbb2 was
decreased. As a consequence, reduced levels of phosphory-
lated Erk were observed, but Akt phosphorylation did not
change (Figure 2D). Phosphorylation of EGFR was greatly
reduced or completely abrogated in all of the resistant tumors,
and phosphorylation of Akt was consistently higher than in un-
treated tumors, suggesting the presence of compensatory
mechanisms of activation of the PI3K pathway in these tumors.
Similarly, phosphorylation of Erbb2 was not restored to un-
treated levels in the A+C-resistant tumors. Similar to the xeno-
grafts discussed previously, A+C-resistant tumors consistently
showed increased pS6, suggesting that increased activation of
mTORC1 may play a role in AR to A+C (Figures 2C and 2D).
Mutations in mTOR Signaling Pathway Genes Are
Associated with Resistance to A+C in Human Tumors
Consistent with the preclinical modeling, we found genetic evi-
dence for potential activation of the mTOR signaling pathway1002 Cell Reports 7, 999–1008, May 22, 2014 ª2014 The Authorsin tumor samples from two (of four analyzed) separate patients
with AR to A+C (Figure 3; Table 1; see Supplemental Information
for patient details). Strikingly, the mutated tumor genes were not
shared between the two patients, but they both converged on
the mTOR pathway. In the first patient, targeted resequencing
of 182 genes using the FoundationOne platform (Table 1; Table
S3) as well as WES revealed that the resected A+C-resistant tu-
mor (Figures 3A and S3A) still harbored both the L858R and
T790M mutations (frequencies of 0.38 of 1,162 reads and 0.24
of 1,279 reads, respectively, in the FoundationOne assay) (Jesel-
sohn et al., 2014). Unexpectedly, two additional mutations were
found in NF2 (c.592C>T_p.R198* at frequency 0.15 of 631 reads
and c.811-2A>T: splice at 0.13 frequency of 1,168 reads). These
twomutations were not detected in the 2006 tumor specimen, as
assessed by amplicon-based deep resequencing (Table 1).
The NF2 gene encodes Merlin, a protein with putative tumor-
suppressive function. Both mutations are predicted to cause
loss of protein function. The R198* mutation is a truncating mu-
tation that causes loss of two-thirds of Merlin and has previously
been described in cancers, including ependymoma (Lamszus
et al., 2001). The c.811-2A>T alteration is a splice-site mutation
that at a minimum affects the FERM domain, important for Mer-
lin’s localization and activation. In support of a functional role of
this mutation, a 69 bp deletion encompassing this exon 9 splice
site and causing NF2 exon 9 skipping has been associated with
familial autosomal dominant intramedullary ependymoma (Zem-
moura et al., 2014).
In different cellular contexts, NF2 has been shown in indepen-
dent studies to negatively regulate EGFR signaling andmTORC1
(Curto et al., 2007; James et al., 2009; Lo´pez-Lago et al., 2009).
To determine whether the mTORC1 pathway was activated in
this sample, we used immunohistochemistry (IHC) to stain the bi-
opsy specimen collected at the time of resistance to A+C with a
pS6 antibody and observed a strong signal (Figure 3B). In sup-
port of a role for NF2 on TKI sensitivity, knockdown of NF2 led
to a decrease in the sensitivity of PC-9 cells to afatinib (Fig-
ure 3C). Importantly, the addition of an mTOR inhibitor, everoli-
mus (RAD001), resensitized PC-9 cells with NF2 knockdown to
afatinib in vitro (Figure 3C). Notably, everolimus alone was not
able to inhibit cell proliferation in cells treated with either control
(scrambled) orNF2 small interfering RNAs (siRNAs) (Figure S3C).
The same effect was observed in HCC827 cells upon cetuximab
treatment (Figure S3B). Moreover, A+C treatment in LUAD
HCC827 cells did not decrease the levels of pS6 upon NF2
knockdown (Figure S3B). Taken together, these patient and
in vitro data suggest that the NF2 mutations were acquired
during treatment on A+C and that NF2 loss leads to activation
of the mTORC1 signaling pathway to mediate drug resistance.
In the second patient, initial molecular analysis of the A+C-
resistant tumor (Figure 3D) did not detect the T790M mutation,
MET amplification, or ERBB2 amplification. Further analysis us-
ing a more recent FoundationOne panel (Frampton et al., 2013)
revealed the presence of the L858R mutation (c.2573T>G;
frequency of 0.19 of 715 reads) plus a mutation in the tuberous
sclerosis 1 (TSC1) gene (c.345_345 delT_p.L116fs*; frequency
0.15 of 399 reads; this sample contained approximately 70% tu-
mor cells) (Table 1; Table S3). The observed L116fs* frameshift
mutation leads to the creation of a stop codon immediately
AB C
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Figure 2. Activation of the mTOR Pathway in A+C-Resistant Mouse LUADs
(A) Intermittent dosing of A+C was performed on a 1-month-on and 1-month-off drug cycle. Doxycycline administration was initiated at weaning and subse-
quently kept constant throughout the life of the animal. Tumor response was evaluated by magnetic resonance imaging (MRI) at the beginning and at the end of
every drug-treatment cycle. Coronal magnetic resonance images of a CCSP-rtTA; TetO-EGFRL858R+T790M mouse subjected to intermittent A+C treatment are
shown. Tumor volume measurements are found below each image. H, heart.
(B) Tumor response inCCSP-rtTA; TetO-EGFRL858R+T790Mmice subjected to the A+C intermittent treatment protocol. Tumor volume is plotted as the percentage
of the tumor volume detected on the pre-cycle MRI. Median tumor volume change is 80% in the first cycle, 22% in the second cycle, and +29% at the third
cycle of A+C.
(C) Hematoxylin and eosin staining (H&E) and IHC performed on paraffin sections of LUADs derived fromCCSP-rtTA; TetO-EGFRL858R+T790M untreatedmice and
mice treated with A+C for 5 days or at resistance to the drug combination (A+C Res). Sections were stained with antibodies to EGFRL858R, pS6, surfactant protein
C (SPC), and thyroid transcription factor (TTF1) as indicated. Original magnification 340 is shown. Scale bars, 20 mm.
(D) Immunoblotting analyses of tumor lysates from LUADs derived from untreated (Untr), A+C-treated (5 dys), or resistant (A+C res) CCSP-rtTA;
TetO-EGFRL858R+T790M mice. Lysates were probed with the indicated antibodies; p, phospho.
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Figure 3. Genetic Alterations Associated with Activation of mTORC1 in Human Lung Tumors Resistant to A+C
(A) Top: disease milestones for patient 1. Time from diagnosis to A+C resistance is indicated by the black arrow. Clinical findings, procedures, and drug
treatments are indicated above the arrow. Molecular findings are shown below the black arrow. Dx, diagnosis; POD, progression of disease; RUL, right upper
lobe; RML, right middle lobe; RLL, right lower lobe; R, right; Mutns, mutations. Bottom: computed tomography scans of the lungs are shown prior to (12.07.10),
during (01.04.11), and at resistance (08.29.11) to A+C. Tumors areas are circled.
(B) Hematoxylin and eosin (H&E; left) and IHC for pS6 (right) of the A+C-resistant tumor harboring the NF2mutations. Original magnification320 is shown. Scale
bars, 50 mm.
(C) Growth inhibition of PC-9 cells after knockdown of NF2 in response to afatinib (left). Viable cells were measured after 72 hr of treatment and plotted relative to
untreated controls. Data are presented as the mean ± SE. Immunoblotting of PC-9 cells showing efficient knockdown of Merlin expression is shown on the right.
Lysates were probed with the indicated antibodies. scrmb, scrambled siRNA.
(D) Top: disease milestones for patient 2. Time from diagnosis to A+C resistance is indicated by the black arrow. Clinical findings, procedures, and drug
treatments are indicated above the arrow.Molecular findings are shown below the black arrow. Dx, diagnosis; POD, progression of disease; RLL, right lower lobe;
Mutn, mutation; LN, lymph node. Bottom, computed tomography scans of the lungs are shown prior (01.09.12) and during treatment with A+C (02.06.12). Tumor
areas are circled.
(E) H&E staining of the excised cervical lymph node from patient 2 (left) and IHC showing phosphorylation of S6 (pS6, right). Scale bars, 50 mm.
(F) Growth inhibition of PC-9 cells after knockdown of TSC1 in response to afatinib (left). Viable cells weremeasured after 72 hr of treatment and plotted relative to
untreated controls. Data are presented as the mean ± SE. Immunoblotting of PC-9 cells showing efficient knockdown of TSC1 expression is shown on the right.
Lysates were probed with the indicated antibodies. scrmb, scrambled siRNA.
1004 Cell Reports 7, 999–1008, May 22, 2014 ª2014 The Authors
Table 1. List of Mutations Detected by Targeted Sequencing in
Patient 1 and Patient 2
Gene Nucleotide Protein
Pre-A+C
(Frequency,
Total Reads)
Post-A+C
(Frequency,
Total Reads)
Patient 1
EGFR c.2573T>G p.L858R positivea 38%, 1,162
EGFR c.2369C>T p.T790M positivea 24%, 1,279
NF2 c.592C>T p.R198* 0%, 2,301 15%, 631
NF2 c.811-2A>T splice 0%, 2,569 13%, 1,168
Patient 2
EGFR c.2573T>G p.L858R 3%, 827 19%, 715
TSC1 c.345_345delT p.L116fs*2 1%, 613 15%, 399
aAs per a 2009 retrospective clinical report (Genzyme) of a 2006 biopsy
sample.downstream of codon 116, truncating the protein. The somatic
status and zygosity of the TSC1 L116fs*2 alteration (see Supple-
mental Experimental Procedures) were consistent with a so-
matic alteration clonally present on a single TSC1 copy in the
tumor, indicating that loss of heterozygosity (LOH) occurred.
The TSC1 mutation status of the pleural fluid collected at diag-
nosis was not assessed due to insufficient tumor material. Foun-
dationOne analysis of the erlotinib-resistant lung specimen
(before A+C) identified the presence of the L858R mutation
(c.2573T>G; frequency of 0.03 of 827 reads) and of the TSC1
mutation (c.345_345 delT_p.L116fs*; frequency 0.01 of 613
reads), indicating that it did preexist treatment with A+C (Table 1;
Table S3). The low allele frequency of both of the mutations
is due to low tumor purity of this sample (10% purity). These
data suggest that selection of the deleterious TSC1 mutant
may have occurred during A+C treatment.
The TSC1 gene encodes for Hamartin, which together with
Tuberin (TSC2) forms a complex that suppresses mTORC1
signaling (Laplante and Sabatini, 2012). To determine whether
this pathway was active in the sample collected after A+C treat-
ment, we performed IHC for pS6 and observed strong staining
(Figure 3E). The functional role of disruption of TSC1 on drug
response was tested using siRNAs. Knockdown of TSC1 in
PC-9 cells led to a decrease in sensitivity of the cells to afatinib,
and sensitivity to afatinib was restored by the addition of evero-
limus (Figure 3F). Moreover, cells treated with either scrambled
or TSC1 siRNAs were not sensitive to everolimus treatment
(Figure S3C). These results indicate that the absence of TSC1
mediates resistance to EGFR-directed therapies by activating
the mTORC1 signaling pathway.
Xenografts and LUADs Resistant to A+C Are Sensitive to
Concurrent EGFR and mTOR Inhibition
Activation of the mTOR pathway in mouse models and patient
samples led us to explore whether A+C-resistant tumors re-
sponded to inhibition of this pathway. To test this, we treated
four CCSP-rtTA; TetO-EGFRL858R+T790M mice with A+C-resis-
tant tumors with rapamycin as a single agent. Rapamycin treat-
ment alone was ineffective in all four cases (Figures 4A and 4C).
This result is in line with previous findings showing that inhibitionof mTOR alone is not sufficient to abolish Akt signaling and that
the combination of an mTOR inhibitor with an RTK inhibitor is
more likely to have antitumor activity (Li et al., 2008; Rodrik-Out-
mezguine et al., 2011). To test whether combined inhibition of
EGFR and mTOR could overcome resistance to A+C, we added
rapamycin to the treatment regimen of CCSP-rtTA; TetO-
EGFRL858R+T790M mice at the time of emergence of resistance
to afatinib plus cetuximab (A+C+R). All eight mice with LUADs
resistant to A+C responded dramatically to the addition of rapa-
mycin (Figures 4B and 4C). In the mice with tumor burden lower
than 600mm3 (six out of eight), tumor shrinkagewas greater than
72% after 1 month of treatment with A+C+R (Figure 4B; Table
S4). We also stained paraffin-embedded sections of A+C-resis-
tant LUADs treated with rapamycin alone or in combination with
A+C with antibodies against phosphohistone H3 and cleaved
caspase-3 (Figure S4). Tumors treated with rapamycin alone
were not growth inhibited, while tumors treated with A+C+R ex-
hibited both proliferation arrest and cell death. We further found
that addition of rapamycin to A+C decreased pS6 in the LUADs
(Figure 4D). All four of the A+C-resistant tumors treated with
rapamycin alone showed activation of EGFR and Erbb2, as ex-
pected by the absence of EGFR-directed therapies (Figure 4D).
To evaluate the effect of concurrent EGFR and mTOR inhibi-
tion in xenografts, we injected 106 cells derived from the A+C-
resistant xenografts 16T-10 and 24T-10 into immunodeficient
mice. Upon the growth of A+C-resistant tumors, mice were
divided into three groups (Figure 4E). One group was maintained
on A+C for 4 weeks (n = 7). The second group was treated with
rapamycin alone (R; n = 2), and the third group was treated with
rapamycin in addition to A+C (A+C+R; n = 5). Tumors in the A+C
combination and rapamycin arms grew throughout the 4 weeks.
In contrast, all of the tumors in mice that received A+C+R
shrank (Figure 4F). Together, these data indicate that inhibition
of mTORC1 can resensitize cells to A+C treatment.
DISCUSSION
We show that resistance to dual inhibition of EGFRL858R+T790M
with A+C is due to activation of mTORC1 signaling in mouse
models. Addition of drugs targeting mTOR resensitizes tumors
to A+C treatment. Consistent with these findings, we have iden-
tified mutations in genes that affect the mTOR signaling cascade
in A+C-resistant biopsy samples from two separate patients with
EGFR mutant lung cancer.
Previous studies have shown that the presence of active
mTORC1 in untreated EGFR-mutant tumors is a direct conse-
quence of mutant EGFR signaling. Effective therapies that
target mutant EGFR lead to a decrease in mTORC1 signaling
and consequent tumor regression. Indeed, in cell lines harbor-
ing EGFR TKI-sensitizing mutations (e.g., EGFRL858R), EGFR
blockade using TKIs leads to a decrease in pS6 equivalent to
that observed with rapamycin, accompanied by a decrease in
cell viability (Li et al., 2007). Further supporting the critical
role of mTORC1 signaling in the maintenance of EGFR-mutant
lung tumors, the combination of either afatinib or HKI-272
with rapamycin together was required to elicit regression of
EGFRL858R+T790M-induced tumors (Li et al., 2007, 2008). Our
study shows that in addition to playing a role in the maintenanceCell Reports 7, 999–1008, May 22, 2014 ª2014 The Authors 1005
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Figure 4. Tumors Resistant to A+C Are Sensitive to Concurrent EGFR and mTOR Inhibition
(A) Coronal MR images of CCSP-rtTA; TetO-EGFRL858R+T790M mouse lungs prior to and upon treatment with rapamycin (R) following the development of
resistance to A+C as indicated in red. Tumor volume measurements are shown.
(B) Coronal magnetic resonance images of CCSP-rtTA; TetO-EGFRL858R+T790M mouse lungs prior to and upon treatment with rapamycin in combination with
afatinib and cetuximab (A+C+R) following the development of resistance to A+C as indicated in red. Tumor volume measurements are shown.
(C) Response of A+C-resistant LUADs from CCSP-rtTA; TetO-EGFRL858R+T790M mice to 4 weeks of treatment with rapamycin alone (R) or in combination with
afatinib and cetuximab (A+C+R). The increase in tumor volume in the presence of A+C before the randomization to R or A+C+R is shown on the left. Tumor
volumes are plotted as the percentage of the tumor volume detected in the precycle magnetic resonance imaging. Median tumor volume change to R is +52%
and to A+C+R is 79%.
(D) Immunoblotting analysis of LUADs resistant to A+C, following 4 weeks of treatment with rapamycin alone or in combination with afatinib and cetuximab.
Lysates were probed with the indicated antibodies; p, phospho.
(E) Strategy used to test the response of A+C-resistant xenograft tumors to concurrent EGFR and mTOR inhibition. Approximately 106 16T-10 or 24T-10 cells
were injected subcutaneously into immunocompromised mice. When tumors reached a volume between 150 and 200 mm3, mice were treated with A+C (n = 14).
When resistance emerged, two mice were switched to rapamycin treatment (R, 2 mg/kg per day) and five mice received A+C+R. The rest of the mice were
maintained on A+C. Mice were treated for 4 weeks from the randomization point.
(F) Tumor response to A+C, rapamycin alone (R), or in combination (A+C+R) in xenografts. Data are plotted as percentage of tumor volume change from the
randomizationpoint. Themedian response toA+C+Rwas75%inxenograftsderived from16T-10cells (left) and91%inxenograftsderived from24T-10cells (right).
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of EGFR-mutant lung tumors, the mTORC1 pathway also plays
a role in resistance to EGFR-directed therapies, specifically
following A+C treatment. First, pS6 is observed in cell lines,
xenografts, and genetically engineered mouse models of A+C-
resistant EGFR-mutant lung cancer. Second, these tumors
regress following the addition of rapamycin to A+C. These data
highlight the importance of mTORC1 for the survival of lung
cancer cells with EGFRmutations and suggest that as resistance
emerges, tumors increasingly rely on mTORC1 activation to
survive.
The presence of a TSC1 frameshift mutation coupledwith LOH
at the same locus in a sample from a patient biopsied upon pro-
gression with A+C provides further evidence for dysregulation
of the mTOR pathway as a mechanism of resistance to A+C.
Indeed, strong pS6 staining was observed in tumor cells in this
sample, and disruption of TSC1 in human EGFR-mutant lung
cancer cell lines increased their viability in the presence of
EGFR TKIs. Unexpectedly, acquired NF2 inactivating mutations
were observed in A+C-resistant specimens from a separate pa-
tient on the same trial. Recent work has found that a downstream
biochemical consequence of NF2 loss is activation mTORC1
(Lo´pez-Lago et al., 2009). We show that the effects of both
TSC1 and NF2 loss can be reversed in cells by treatment with
a rapalog, suggesting that the presence of genomic changes in
these genes indicates sensitivity to mTOR inhibition. Further
studies to determine the prevalence of NF2 and TSC1mutations
in EGFR-mutant lung cancer are ongoing.
mTORC1 represents the output of several signaling pathways
and external stimuli. In addition to genetic mechanisms like
those described above that lead to its activation, it can be
engaged through nongenetic mechanisms. Increased growth
factor receptor signaling, through, for example, IGF1R, activates
mTORC1 through the PI3K pathway. In this setting, one would
expect to observe higher levels of phosphorylation of mTORC1
and AKT. Consistent with the possibility of similar mechanisms
occurring in some of our models, we observed increased phos-
phorylation of AKT in the #16 xenograft-derived tumors and in
the A+C-resistant genetically engineered mouse model tumors
(Figures 1D and 2D). An increase in the levels of phosphorylation
of IGF1R was indeed observed in the #16-derived tumors (data
not shown) and may explain the increased mTORC1 signaling
found in these tumors. These results also highlight how activa-
tion of mTORC1 can occur both via signals upstream and down-
stream of AKT. Moreover, our data from cell lines, xenografts,
and patient samples suggest that mTORC1 activation acts cell
autonomously in the tumor cells to confer resistance. Whether
this pathway is also activated in other cells in the tumor microen-
vironment cannot be excluded and is under further investigation.
Our findings suggest that patients with AR to A+C may benefit
from drug combinations that include EGFR-directed therapies
and mTOR inhibitors. In this regard, a phase IB trial of afatinib
with the rapalog sirolimus in patients with EGFR-mutant lung
cancer is currently ongoing. Phase III trials of A+C in patients
with TKI-naive and refractory EGFR-mutant lung cancer are
planned. Inhibition of mTOR in this context may delay resistance.
Due to concerns about the toxicity of this multidrug combina-
tion, it will be important to use preclinical models to determine
whether continuous or intermittent dosing of the mTOR inhibitorare equally effective at countering drug resistance. Moreover,
rapalogs only partially block downstream functions of mTOR in
contrast to mTORC1/2 kinase inhibitors. Investigation of these
latter novel agents will be informative to determine their efficacy
in the context of EGFR-mutant lung cancer. Finally, the recent
development of mutant-specific EGFR inhibitors that induce
reduced toxicity due to less inhibition of wild-type EGFR may
open the door to the use of drug combinations including those
of EGFR inhibitors with mTOR inhibitors (Walter et al., 2013).
In summary, resistance to targeted therapies remains the
major hurdle to the long-term success of EGFR-directed thera-
pies. Our data in multiple preclinical models and human tumor
samples show increased mTORC1 signaling after long-term
treatment with A+C, identifying this node as a critical vulnera-
bility of drug-resistant cells.
EXPERIMENTAL PROCEDURES
Transgenic Mice and Xenografts
All animals were kept in pathogen-free housing under guidelines approved
by the Memorial Sloan Kettering Cancer Center (MSKCC) and Yale institu-
tional animal care and use committees. TetO-EGFRL858R+T790M mice (Regales
et al., 2007) and CCSP-rtTA mice were previously described (Tichelaar et al.,
2000). For xenografts, 8-week-old nu/nu athymic nude mice (Harlan Labs)
were injected subcutaneously with 10 3 106 PC-9/BRc1 cells together with
Matrigel (BD Biosciences). Mice were randomized to receive either drug
diluent alone (vehicle) or A+C. Tumor size was measured twice a week
using calipers. To further propagate A+C-resistant tumors, these were
minced and immediately injected subcutaneously with Matrigel (tumor #16)
or cultured for 2 weeks then reinjected subcutaneously into immunodeficient
mice (tumor #24). Afatinib (produced by the Organic Synthesis Core Facility at
MSKCC) was suspended in 0.5% (w/v) methylcellulose and administered
orally (25 mg/kg per day 5 days a week). Cetuximab (Erbitux; Bristol-Myers
Squibb and Eli Lilly Pharmaceuticals) was purchased and administered
intraperitoneally (1 mg twice a week). Rapamycin (LC Laboratories) was sus-
pended in 0.5% carboxymethylcellulose and given orally at 2 mg/kg per day
5 days a week.
Cell Culture
Human LUAD cell lines PC-9, PC-9/BRc1, andHCC827were used (Chmielecki
et al., 2011). A+C-resistant cells, obtained from xenograft tumors, were kept in
culture in presence of afatinib (250 nM) and cetuximab (10 mg/ml).
Immunoblotting
Cells and crushed tumors were lysed in ice-cold RIPA lysis buffer (50 mM
Tris [pH 8.0], 150 mMNaCl, 5 mMMgCl, 1% Triton X-100, 0.5% sodium deox-
ycholate, 0.1%SDS, and protease and phosphatase inhibitor cocktail; Thermo
Scientific). For cell-treatment studies, cells were starved overnight, treated
with drugs for 8 hours, and washed twice with cold PBS before lysate prepa-
ration. Equal amounts of total protein were separated by SDS-PAGE and
probed as indicated. Signals were detected using either SuperSignal West
Pico or Femto chemiluminescent substrates (Pierce Biotechnology). For a
list of antibodies, see Supplemental Experimental Procedures.
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